ArticleBlood advances2024

Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome.

Courtney D DiNardo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.